7 results on '"Gunsilius C"'
Number of results to display per page
Search Results
2. Abstracts from the 4th ImmunoTherapy of Cancer Conference
- Author
-
Ženka, J., primary, Caisová, V., additional, Uher, O., additional, Nedbalová, P., additional, Kvardová, K., additional, Masáková, K., additional, Krejčová, G., additional, Paďouková, L., additional, Jochmanová, I., additional, Wolf, K. I., additional, Chmelař, J., additional, Kopecký, J., additional, Loumagne, L., additional, Mestadier, J., additional, D’agostino, S., additional, Rohaut, A., additional, Ruffin, Y., additional, Croize, V., additional, Lemaître, O., additional, Sidhu, S. S., additional, Althammer, S., additional, Steele, K., additional, Rebelatto, M., additional, Tan, T., additional, Wiestler, T., additional, Spitzmueller, A., additional, Korn, R., additional, Schmidt, G., additional, Higgs, B., additional, Li, X., additional, Shi, L., additional, Jin, X., additional, Ranade, K., additional, Koeck, S., additional, Amann, A., additional, Gamerith, G., additional, Zwierzina, M., additional, Lorenz, E., additional, Zwierzina, H., additional, Kern, J., additional, Riva, M., additional, Baert, T., additional, Coosemans, A., additional, Giovannoni, R., additional, Radaelli, E., additional, Gsell, W., additional, Himmelreich, U., additional, Van Ranst, M., additional, Xing, F., additional, Qian, W., additional, Dong, C., additional, Xu, X., additional, Guo, S., additional, Shi, Q., additional, Quandt, D., additional, Seliger, B., additional, Plett, C., additional, Amberger, D. C., additional, Rabe, A., additional, Deen, D., additional, Stankova, Z., additional, Hirn, A., additional, Vokac, Y., additional, Werner, J., additional, Krämer, D., additional, Rank, A., additional, Schmid, C., additional, Schmetzer, H., additional, Guerin, M., additional, Weiss, J. M., additional, Regnier, F., additional, Renault, G., additional, Vimeux, L., additional, Peranzoni, E., additional, Feuillet, V., additional, Thoreau, M., additional, Guilbert, T., additional, Trautmann, A., additional, Bercovici, N., additional, Doraneh-Gard, F., additional, Boeck, C. L., additional, Gunsilius, C., additional, Kugler, C., additional, Schmohl, J., additional, Kraemer, D., additional, Ismann, B., additional, Schmetzer, H. M., additional, Markota, A., additional, Ochs, C., additional, May, P., additional, Gottschlich, A., additional, Gosálvez, J. Suárez, additional, Karches, C., additional, Wenk, D., additional, Endres, S., additional, Kobold, S., additional, Hilmenyuk, T., additional, Klar, R., additional, Jaschinski, F., additional, Augustin, F., additional, Manzl, C., additional, Hoflehner, E., additional, Moser, P., additional, Zelger, B., additional, Köck, S., additional, Schäfer, G., additional, Öfner, D., additional, Maier, H., additional, Sopper, S., additional, Prado-Garcia, H., additional, Romero-Garcia, S., additional, Sandoval-Martínez, R., additional, Puerto-Aquino, A., additional, Lopez-Gonzalez, J., additional, Rumbo-Nava, U., additional, Van Hoylandt, A., additional, Busschaert, P., additional, Vergote, I., additional, Laengle, J., additional, Pilatova, K., additional, Budinska, E., additional, Bencsikova, B., additional, Sefr, R., additional, Nenutil, R., additional, Brychtova, V., additional, Fedorova, L., additional, Hanakova, B., additional, Zdrazilova-Dubska, L., additional, Allen, Chris, additional, Ku, Yuan-Chieh, additional, Tom, Warren, additional, Sun, Yongming, additional, Pankov, Alex, additional, Looney, Tim, additional, Hyland, Fiona, additional, Au-Young, Janice, additional, Mongan, Ann, additional, Becker, A., additional, Tan, J. B. L., additional, Chen, A., additional, Lawson, K., additional, Lindsey, E., additional, Powers, J. P., additional, Walters, M., additional, Schindler, U., additional, Young, S., additional, Jaen, J. C., additional, Yin, S., additional, Chen, Y., additional, Gullo, I., additional, Gonçalves, G., additional, Pinto, M. L., additional, Athelogou, M., additional, Almeida, G., additional, Huss, R., additional, Oliveira, C., additional, Carneiro, F., additional, Merz, C., additional, Sykora, J., additional, Hermann, K., additional, Hussong, R., additional, Richards, D. M., additional, Fricke, H., additional, Hill, O., additional, Gieffers, C., additional, Pinho, M. P., additional, Barbuto, J. A. M., additional, McArdle, S. E., additional, Foulds, G., additional, Vadakekolathu, J. N., additional, Abdel-Fatah, T. M. A., additional, Johnson, C., additional, Hood, S., additional, Moseley, P., additional, Rees, R. C., additional, Chan, S. Y. T., additional, Pockley, A. G., additional, Rutella, S., additional, Geppert, C., additional, Hartmann, A., additional, Kumar, K. Senthil, additional, Gokilavani, M., additional, Wang, S., additional, Redondo-Müller, M., additional, Heinonen, K., additional, Marschall, V., additional, Thiemann, M., additional, Zhang, L., additional, Mao, B., additional, Jin, Y., additional, Zhai, G., additional, Li, Z., additional, Wang, Z., additional, An, X., additional, Qiao, M., additional, Zhang, J., additional, Weber, J., additional, Kluger, H., additional, Halaban, R., additional, Sznol, M., additional, Roder, H., additional, Roder, J., additional, Grigorieva, J., additional, Asmellash, S., additional, Meyer, K., additional, Steingrimsson, A., additional, Blackmon, S., additional, Sullivan, R., additional, Sutanto, W., additional, Guenther, T., additional, Schuster, F., additional, Salih, H., additional, Babor, F., additional, Borkhardt, A., additional, Kim, Y., additional, Oh, I., additional, Park, C., additional, Ahn, S., additional, Na, K., additional, Song, S., additional, Choi, Y., additional, Poprach, A., additional, Lakomy, R., additional, Selingerova, I., additional, Demlova, R., additional, Kozakova, S., additional, Valik, D., additional, Petrakova, K., additional, Vyzula, R., additional, Aguilar-Cazares, D., additional, Galicia-Velasco, M., additional, Camacho-Mendoza, C., additional, Islas-Vazquez, L., additional, Chavez-Dominguez, R., additional, Gonzalez-Gonzalez, C., additional, Lopez-Gonzalez, J. S., additional, Yang, S., additional, Moynihan, K. D., additional, Noh, M., additional, Bekdemir, A., additional, Stellacci, F., additional, Irvine, D. J., additional, Volz, B., additional, Kapp, K., additional, Oswald, D., additional, Wittig, B., additional, Schmidt, M., additional, Kleef, R., additional, Bohdjalian, A., additional, McKee, D., additional, Moss, R. W., additional, Saeed, Mesha, additional, Zalba, Sara, additional, Debets, Reno, additional, ten Hagen, Timo L. M., additional, Javed, S., additional, Becher, J., additional, Koch-Nolte, F., additional, Haag, F., additional, Gordon, E. M., additional, Sankhala, K. K., additional, Stumpf, N., additional, Tseng, W., additional, Chawla, S. P., additional, Suárez, N. González, additional, Báez, G. Bergado, additional, Rodríguez, M. Cruz, additional, Pérez, A. Gutierrez, additional, García, L. Chao, additional, Fernández, D. Hernández, additional, Pous, J. Raymond, additional, Ramírez, B. Sánchez, additional, Jacoberger-Foissac, C., additional, Saliba, H., additional, Seguin, C., additional, Brion, A., additional, Frisch, B., additional, Fournel, S., additional, Heurtault, B., additional, Otterhaug, T., additional, Håkerud, M., additional, Nedberg, A., additional, Edwards, V., additional, Selbo, P., additional, Høgset, A., additional, Jaitly, T., additional, Dörrie, J., additional, Schaft, N., additional, Gross, S., additional, Schuler-Thurner, B., additional, Gupta, S., additional, Taher, L., additional, Schuler, G., additional, Vera, J., additional, Rataj, F., additional, Kraus, F., additional, Grassmann, S., additional, Chaloupka, M., additional, Lesch, S., additional, Heise, C., additional, Cadilha, B. M. Loureiro, additional, and Dorman, K., additional
- Published
- 2017
- Full Text
- View/download PDF
3. Abstracts from the 4th ImmunoTherapy of Cancer Conference
- Author
-
Ženka, J., Caisová, V., Uher, O., Nedbalová, P., Kvardová, K., Masáková, K., Krejčová, G., Paďouková, L., Jochmanová, I., Wolf, K. I., Chmelař, J., Kopecký, J., Loumagne, L., Mestadier, J., D’agostino, S., Rohaut, A., Ruffin, Y., Croize, V., Lemaître, O., Sidhu, S. S., Althammer, S., Steele, K., Rebelatto, M., Tan, T., Wiestler, T., Spitzmueller, A., Korn, R., Schmidt, G., Higgs, B., Li, X., Shi, L., Jin, X., Ranade, K., Koeck, S., Amann, A., Gamerith, G., Zwierzina, M., Lorenz, E., Zwierzina, H., Kern, J., Riva, M., Baert, T., Coosemans, A., Giovannoni, R., Radaelli, E., Gsell, W., Himmelreich, U., Van Ranst, M., Xing, F., Qian, W., Dong, C., Xu, X., Guo, S., Shi, Q., Quandt, D., Seliger, B., Plett, C., Amberger, D. C., Rabe, A., Deen, D., Stankova, Z., Hirn, A., Vokac, Y., Werner, J., Krämer, D., Rank, A., Schmid, C., Schmetzer, H., Guerin, M., Weiss, J. M., Regnier, F., Renault, G., Vimeux, L., Peranzoni, E., Feuillet, V., Thoreau, M., Guilbert, T., Trautmann, A., Bercovici, N., Doraneh-Gard, F., Boeck, C. L., Gunsilius, C., Kugler, C., Schmohl, J., Kraemer, D., Ismann, B., Schmetzer, H. M., Markota, A., Ochs, C., May, P., Gottschlich, A., Gosálvez, J. Suárez, Karches, C., Wenk, D., Endres, S., Kobold, S., Hilmenyuk, T., Klar, R., Jaschinski, F., Augustin, F., Manzl, C., Hoflehner, E., Moser, P., Zelger, B., Köck, S., Schäfer, G., Öfner, D., Maier, H., Sopper, S., Prado-Garcia, H., Romero-Garcia, S., Sandoval-Martínez, R., Puerto-Aquino, A., Lopez-Gonzalez, J., Rumbo-Nava, U., Van Hoylandt, A., Busschaert, P., Vergote, I., Laengle, J., Pilatova, K., Budinska, E., Bencsikova, B., Sefr, R., Nenutil, R., Brychtova, V., Fedorova, L., Hanakova, B., Zdrazilova-Dubska, L., Allen, Chris, Ku, Yuan-Chieh, Tom, Warren, Sun, Yongming, Pankov, Alex, Looney, Tim, Hyland, Fiona, Au-Young, Janice, Mongan, Ann, Becker, A., Tan, J. B. L., Chen, A., Lawson, K., Lindsey, E., Powers, J. P., Walters, M., Schindler, U., Young, S., Jaen, J. C., Yin, S., Chen, Y., Gullo, I., Gonçalves, G., Pinto, M. L., Athelogou, M., Almeida, G., Huss, R., Oliveira, C., Carneiro, F., Merz, C., Sykora, J., Hermann, K., Hussong, R., Richards, D. M., Fricke, H., Hill, O., Gieffers, C., Pinho, M. P., Barbuto, J. A. M., McArdle, S. E., Foulds, G., Vadakekolathu, J. N., Abdel-Fatah, T. M. A., Johnson, C., Hood, S., Moseley, P., Rees, R. C., Chan, S. Y. T., Pockley, A. G., Rutella, S., Geppert, C., Hartmann, A., Kumar, K. Senthil, Gokilavani, M., Wang, S., Redondo-Müller, M., Heinonen, K., Marschall, V., Thiemann, M., Zhang, L., Mao, B., Jin, Y., Zhai, G., Li, Z., Wang, Z., An, X., Qiao, M., Zhang, J., Weber, J., Kluger, H., Halaban, R., Sznol, M., Roder, H., Roder, J., Grigorieva, J., Asmellash, S., Meyer, K., Steingrimsson, A., Blackmon, S., Sullivan, R., Sutanto, W., Guenther, T., Schuster, F., Salih, H., Babor, F., Borkhardt, A., Kim, Y., Oh, I., Park, C., Ahn, S., Na, K., Song, S., Choi, Y., Poprach, A., Lakomy, R., Selingerova, I., Demlova, R., Kozakova, S., Valik, D., Petrakova, K., Vyzula, R., Aguilar-Cazares, D., Galicia-Velasco, M., Camacho-Mendoza, C., Islas-Vazquez, L., Chavez-Dominguez, R., Gonzalez-Gonzalez, C., Lopez-Gonzalez, J. S., Yang, S., Moynihan, K. D., Noh, M., Bekdemir, A., Stellacci, F., Irvine, D. J., Volz, B., Kapp, K., Oswald, D., Wittig, B., Schmidt, M., Kleef, R., Bohdjalian, A., McKee, D., Moss, R. W., Saeed, Mesha, Zalba, Sara, Debets, Reno, ten Hagen, Timo L. M., Javed, S., Becher, J., Koch-Nolte, F., Haag, F., Gordon, E. M., Sankhala, K. K., Stumpf, N., Tseng, W., Chawla, S. P., Suárez, N. González, Báez, G. Bergado, Rodríguez, M. Cruz, Pérez, A. Gutierrez, García, L. Chao, Fernández, D. Hernández, Pous, J. Raymond, Ramírez, B. Sánchez, Jacoberger-Foissac, C., Saliba, H., Seguin, C., Brion, A., Frisch, B., Fournel, S., Heurtault, B., Otterhaug, T., Håkerud, M., Nedberg, A., Edwards, V., Selbo, P., Høgset, A., Jaitly, T., Dörrie, J., Schaft, N., Gross, S., Schuler-Thurner, B., Gupta, S., Taher, L., Schuler, G., Vera, J., Rataj, F., Kraus, F., Grassmann, S., Chaloupka, M., Lesch, S., Heise, C., Cadilha, B. M. Loureiro, and Dorman, K.
- Subjects
Meeting Abstracts - Full Text
- View/download PDF
4. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes.
- Author
-
Rackl E, Li L, Klauer LK, Ugur S, Pepeldjiyska E, Seidel CL, Gunsilius C, Weinmann M, Doraneh-Gard F, Reiter N, Plett C, Amberger DC, Bojko P, Kraemer D, Schmohl J, Rank A, Schmid C, and Schmetzer HM
- Subjects
- Humans, Dendritic Cells, Lymphocyte Activation, Cytokines metabolism, Integrins metabolism, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Leukemia, Myeloid, Acute metabolism
- Abstract
Integrin beta 7 (β7), a subunit of the integrin receptor, is expressed on the surface of immune cells and mediates cell-cell adhesions and interactions, e.g., antitumor or autoimmune reactions. Here, we analyzed, whether the stimulation of immune cells by dendritic cells (of leukemic derivation in AML patients or of monocyte derivation in healthy donors) leads to increased/leukemia-specific β7 expression in immune cells after T-cell-enriched mixed lymphocyte culture-finally leading to improved antileukemic cytotoxicity. Healthy, as well as AML and MDS patients' whole blood (WB) was treated with Kit-M (granulocyte-macrophage colony-stimulating factor (GM-CSF) + prostaglandin E1 (PGE1)) or Kit-I (GM-CSF + Picibanil) in order to generate DCs (DC
leu or monocyte-derived DC), which were then used as stimulator cells in MLC. To quantify antigen/leukemia-specific/antileukemic functionality, a degranulation assay (DEG), an intracellular cytokine assay (INTCYT) and a cytotoxicity fluorolysis assay (CTX) were used. (Leukemia-specific) cell subtypes were quantified via flow cytometry. The Kit treatment of WB (compared to the control) resulted in the generation of DC/DCleu , which induced increased activation of innate and adaptive cells after MLC. Kit-pretreated WB (vs. the control) led to significantly increased frequencies of β7-expressing T-cells, degranulating and intracellular cytokine-producing β7-expressing immune cells and, in patients' samples, increased blast lysis. Positive correlations were found between the Kit-M-mediated improvement of blast lysis (vs. the control) and frequencies of β7-expressing T-cells. Our findings indicate that DC-based immune therapies might be able to specifically activate the immune system against blasts going along with increased frequencies of (leukemia-specific) β7-expressing immune cells. Furthermore, β7 might qualify as a predictor for the efficiency and the success of AML and/or MDS therapies., Competing Interests: H.M.S. is involved with Modiblast Pharma GmbH (Oberhaching, Germany), which holds the European Patent 15 801 987.7-1118 and US Patent 15-517627, “Use of immunomodulatory effective compositions for the immunotherapeutic treatment of patients suffering from myeloid leukemias”.- Published
- 2022
- Full Text
- View/download PDF
5. Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia.
- Author
-
Plett C, Klauer LK, Amberger DC, Ugur S, Rabe A, Fischer Z, Deen D, Hirn-Lopez A, Gunsilius C, Werner JO, Schmohl J, Krämer D, Rank A, Schmid C, and Schmetzer HM
- Subjects
- Biomarkers, Cell Proliferation, Dendritic Cells, Humans, Prostaglandins pharmacology, Prostaglandins E pharmacology, Leukemia, Myeloid, Acute
- Abstract
(Leukaemia derived) dendritic cells (DC, DC
leu ) are potent stimulators of anti-leukaemic activity in acute myeloid leukaemia (AML) and can be generated with immunomodulatory kits containing granulocyte-macrophage-colony-stimulating-factor (GM-CSF), prostaglandin-E1 (PGE1 ), prostaglandin-E2 (PGE2 ) and/or picibanil (OK-321). Potential adverse effects initiated through kits, especially the proliferation of blasts, must be ruled out to ensure treatment safety. We quantified proliferating blasts with the proliferation markers CD71 and Ki-67 and the novel proliferation marker IPO-38 before and after kit treatment ex vivo. IPO-38 hereby appeared to be the most sensitive marker; a combination with CD71 may add value when assessing proliferation kinetics. Kit treatment did not or only slightly (<5%) induce blast proliferation in most cases. An induction of blast proliferation was only found in single cases and could be compensated by DCleu -induced anti-leukaemic activity in most times. Overall, we appraise kit treatment to be safe in vivo., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Modiblast Pharma GmbH (Oberhaching, Germany) holds the European Patent 15,801,987.7–1118 and US Patent 15–517,627 “Use of immunomodulatory effective compositions for the immunotherapeutic treatment of patients suffering from myeloid leukemias”, in which Helga Maria Schmetzer is involved., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
6. Generation of Leukaemia-Derived Dendritic Cells (DC leu ) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations.
- Author
-
Schwepcke C, Klauer LK, Deen D, Amberger DC, Fischer Z, Doraneh-Gard F, Gunsilius C, Hirn-Lopez A, Kroell T, Tischer J, Weinmann M, Werner JO, Rank A, Schmid C, and Schmetzer HM
- Subjects
- Dendritic Cells, Humans, Picibanil, Prostaglandins, Prostaglandins E, Granulocyte-Macrophage Colony-Stimulating Factor pharmacology, Leukemia, Myeloid, Acute therapy
- Abstract
Dendritic cells (DC) and leukaemia derived DC (DC
leu ) are potent stimulators of anti-leukaemic activity in acute myeloid leukaemia (AML) and can be generated from mononuclear cells in vitro following standard DC/DCleu -generating protocols. With respect to future clinical applications though, DC/DCleu -generating protocols specifically designed for application in a whole-blood-(WB)-environment must be established. Therefore, we developed ten new DC/DCleu -generating protocols (kits; Kit-A/-C/-D/-E/-F/-G/-H/-I/-K/-M) for the generation of DC/DCleu from leukaemic WB, containing calcium-ionophore, granulocyte-macrophage-colony-stimulating-factor (GM-CSF), tumour-necrosis-factor-alpha, prostaglandin-E1 (PGE1 ), prostaglandin-E2 (PGE2 ) and/or picibanil (OK-432). All protocols were evaluated regarding their performance in generating DC/DCleu using refined classification and/or ranking systems; DC/DCleu were evaluated regarding their performance in stimulating anti-leukaemic activity using a cytotoxicity fluorolysis assay. Overall, we found the new kits capable to generate (mature) DC/DCleu from leukaemic WB. Through refined classification and ranking systems, we were able to select Kit-I (GM-CSF + OK-432), -K (GM-CSF + PGE2 ) and -M (GM-CSF + PGE1 ) as the most efficient kits in generating (mature) DC/DCleu , which are further competent to stimulate immunoreactive cells to show an improved anti-leukaemic cytotoxicity as well. This great performance of Kit-I, -K and -M in mediating DC/DCleu -based anti-leukaemic immunity in a WB-environment in vitro constitutes an important and directive step for translating DC/DCleu -based immunotherapy of AML into clinical application.- Published
- 2022
- Full Text
- View/download PDF
7. PGE 1 -Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood.
- Author
-
Amberger DC, Doraneh-Gard F, Gunsilius C, Weinmann M, Möbius S, Kugler C, Rogers N, Böck C, Ködel U, Werner JO, Krämer D, Eiz-Vesper B, Rank A, Schmid C, and Schmetzer HM
- Subjects
- Adult, Aged, Biomarkers, Cell Differentiation drug effects, Cytokines metabolism, Female, Flow Cytometry, Humans, Immunomodulation drug effects, Immunophenotyping, Leukemia, Myeloid, Acute metabolism, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear metabolism, Male, Middle Aged, Picibanil pharmacology, Young Adult, Alprostadil pharmacology, Dendritic Cells cytology, Dendritic Cells drug effects
- Abstract
Dendritic cells (DCs) and leukemia-derived DC (DC
leu ) are potent stimulators of various immunoreactive cells and they play a pivotal role in the (re-) activation of the immune system. As a potential treatment tool for patients with acute myeloid leukemia, we developed and analyzed two new PGE1 -containing protocols (Pici-PGE1 , Kit M) to generate DC/DCleu ex vivo from leukemic peripheral blood mononuclear cells (PBMCs) or directly from leukemic whole blood (WB) to simulate physiological conditions. Pici-PGE1 generated significantly higher amounts of DCs from leukemic and healthy PBMCs when compared to control and comparable amounts as the already established protocol Pici-PGE2 . The proportions of sufficient DC-generation were even higher after DC/DCleu -generation with Pici-PGE1 . With Kits, it was possible to generate DCs and DCleu directly from leukemic and healthy WB without induction of blast proliferation. The average amounts of generated DCs and DCleu -subgroups were comparable with all Kits. The PGE1 containing Kit M generated significantly higher amounts of mature DCs when compared to the PGE2 -containing Kit K and increased the anti-leukemic-activity. In summary PGE1 -containing protocols were suitable for generating DC/DCleu from PBMCs as well as from WB, which reliably (re-) activated immunoreactive cells, improved the overall ex vivo anti-leukemic activity, and influenced cytokine-release-profiles.- Published
- 2019
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.